Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: Stock Traders Daily
|
$495.00
|
|
Provider: GlobalData
|
$250.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Perrigo Co Acquires Remaining Stake In Cobrek Pharmaceuticals, Inc. For Approximately $45 Million
Perrigo Co announced that it has signed a definitive merger agreement and has completed the acquisition of Cobrek Pharmaceuticals, Inc. (Cobrek), a privately-held, Chicago, Illinois-based drug development company, for approximately $45 million on a cash free and debt free basis.
Latest Key Developments in Pharmaceuticals
- Nattopharma ASA Maintains FY 2013 Revenue Guidance
- Grifols SA’s Study Demonstrates Higher Dose Of PROLASTIN-C Increases Levels Of Alpha1-PI To Within Normal Range In Patients With AAT Deficiency-DJ
- Protalex Inc Announces Positive Interim Review of Phase 1b Trial Of PRTX-100 in Rheumatoid Arthritis By Independent Data Safety Monitoring Committee
- Pfizer Inc Announces Plan For Split-Off Of Zoetis Inc
- Share this
- Link this
- Digg this
Follow Reuters